Management of women with clear cell endometrial cancer. A Society of Gynecologic Oncology (SGO) review

Gynecologic Oncology

Volumn 113, Issue 2, 2009, Pages 277-283

  Olawaiye, Alexander B ^a   Boruta II, David M ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chemotherapy; Clear cell; Radiotherapy; Staging

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

ADJUVANT THERAPY; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CELL STRUCTURE; CLEAR CELL CARCINOMA; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; KIDNEY CANCER; LYMPHADENECTOMY; MEDICAL SOCIETY; META ANALYSIS; NEUROTOXICITY; PATIENT CARE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SALPINGOOOPHORECTOMY; SYSTEMATIC REVIEW;

ADENOCARCINOMA, CLEAR CELL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS;

EID: 63749104453     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.02.003     Document Type: Review

References (59)

1. Society AC. Estimated new cancer cases and deaths by sex, US, 2008. Cancer Facts & Figures 2008. 2008:4.
2. McMeekin D.S., Filiaci V.L., Thigpen J.T., Gallion H.H., Fleming G.F., and Rodgers W.H. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol. Oncol. 106 1 (2007 Jul) 16-22
3. Modesitt S.C., Tian C., Kryscio R., Thigpen J.T., Randall M.E., Gallion H.H., et al. Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study. Gynecol. Oncol. 105 1 (2007 Apr) 59-65
4. Gallion H.H., Brunetto V.L., Cibull M., Lentz S.S., Reid G., Soper J.T., et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 20 (2003 Oct 15) 3808-3813
5. Thigpen J.T., Brady M.F., Homesley H.D., Malfetano J., DuBeshter B., Burger R.A., et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J. Clin. Oncol. 22 19 (2004 Oct 1) 3902-3908
6. Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 22 11 (2004 Jun 1) 2159-2166
7. Abeler V.M., and Kjorstad K.E. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. Gynecol. Oncol. 40 3 (1991 Mar) 207-217
8. Carcangiu M.L., and Chambers J.T. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. Int. J. Gynecol. Pathol. 14 1 (1995 Jan) 30-38
9. Clement P.B., and Young R.H. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv. Anat. Pathol. 11 3 (2004 May) 117-142
10. Zorn K.K., Bonome T., Gangi L., Chandramouli G.V., Awtrey C.S., Gardner G.J., et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin. Cancer. Res. 11 18 (2005 Sep 15) 6422-6430
11. Fadare O., Liang S.X., Ulukus E.C., Chambers S.K., and Zheng W. Precursors of endometrial clear cell carcinoma. Am. J. Surg. Pathol. 30 12 (2006 Dec) 1519-1530
12. Hoffman K., Nekhlyudov L., and Deligdisch L. Endometrial carcinoma in elderly women. Gynecol. Oncol. 58 2 (1995 Aug) 198-201
13. Magriples U., Naftolin F., Schwartz P.E., and Carcangiu M.L. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J. Clin. Oncol. 11 3 (1993 Mar) 485-490
14. Gu M., Shi W., Barakat R.R., Thaler H.T., and Saigo P.E. Pap smears in women with endometrial carcinoma. Acta. Cytol. 45 4 (2001 Jul-Aug) 555-560
15. Eddy G.L., Wojtowycz M.A., Piraino P.S., and Mazur M.T. Papanicolaou smears by the Bethesda system in endometrial malignancy: utility and prognostic importance. Obstet. Gynecol. 90 6 (1997 Dec) 999-1003
16. Demirkiran F., Arvas M., Erkun E., Kosebay D., Isiloglu H., Aktas E., et al. The prognostic significance of cervico-vaginal cytology in endometrial cancer. Eur. J. Gynaecol. Oncol. 16 5 (1995) 403-409
17. Huang G.S., Gebb J.S., Einstein M.H., Shahabi S., Novetsky A.P., and Goldberg G.L. Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. Am. J. Obstet. Gynecol. 196 3 (2007 Mar) 243 e1-5
18. Wang J., Wieslander C., Hansen G., Cass I., Vasilev S., and Holschneider C.H. Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers. Gynecol. Oncol. 101 1 (2006 Apr) 120-125
19. Lax S.F., Pizer E.S., Ronnett B.M., and Kurman R.J. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Human. Pathol. 29 6 (1998 Jun) 551-558
20. Creasman W.T., Kohler M.F., Odicino F., Maisonneuve P., and Boyle P. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol. Oncol. 95 3 (2004 Dec) 593-596
21. Jones D.E., Creasman W.T., Dombroski R.A., Lentz S.S., and Waeltz J.L. Evaluation of the atypical Pap smear. Am. J. Obstet. Gynecol. 157 3 (1987 Sep) 544-549
22. Boronow R.C., Morrow C.P., Creasman W.T., Disaia P.J., Silverberg S.G., Miller A., et al. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet. Gynecol. 63 6 (1984 Jun) 825-832
23. Creasman W.T., Morrow C.P., Bundy B.N., Homesley H.D., Graham J.E., and Heller P.B. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer 60 8 Suppl (1987 Oct 15) 2035-2041
24. Morrow C.P., Bundy B.N., Kurman R.J., Creasman W.T., Heller P., Homesley H.D., et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol. Oncol. 40 1 (1991 Jan) 55-65
25. Cowles T.A., Magrina J.F., Masterson B.J., and Capen C.V. Comparison of clinical and surgical-staging in patients with endometrial carcinoma. Obstet. Gynecol. 66 3 (1985 Sep) 413-416
26. Averette H.E., Donato D.M., Lovecchio J.L., and Sevin B.U. Surgical staging of gynecologic malignancies. Cancer 60 8 Suppl (1987 Oct 15) 2010-2020
27. Thomas M., Mariani A., Wright J.D., Madarek E.O., Powell M.A., Mutch D.G., et al. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. Gynecol. Oncol. 108 2 (2008 Feb) 293-297
28. Saygili U., Kavaz S., Altunyurt S., Uslu T., Koyuncuoglu M., and Erten O. Omentectomy, peritoneal biopsy and appendectomy in patients with clinical stage I endometrial carcinoma. Int. J. Gynecol. Cancer. 11 6 (2001 Nov-Dec) 471-474
29. Sherman M.E., Bitterman P., Rosenshein N.B., Delgado G., and Kurman R.J. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am. J. Surg. Pathol. 16 6 (1992 Jun) 600-610
30. Kupelian P.A., Eifel P.J., Tornos C., Burke T.W., Delclos L., and Oswald M.J. Treatment of endometrial carcinoma with radiation therapy alone. Int. J. Radiat. Oncol. Biol. Phys. 27 4 (1993 Nov 15) 817-824
31. Reisinger S.A., Staros E.B., Feld R., Mohiuddin M., and Lewis G.C. Preoperative radiation therapy in clinical stage II endometrial carcinoma. Gynecol. Oncol. 45 2 (1992 May) 174-178
32. Lanciano R.M., Curran Jr. W.J., Greven K.M., Fanning J., Stafford P., Randall M.E., et al. Influence of grade, histologic subtype, and timing of radiotherapy on outcome among patients with stage II carcinoma of the endometrium. Gynecol. Oncol. 39 3 (1990 Dec) 368-373
33. Smith R.S., Kapp D.S., Chen Q., and Teng N.N. Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 48 3 (2000 Oct 1) 767-778
34. Stewart K.D., Martinez A.A., Weiner S., Podratz K., Stromberg J.S., Schray M., et al. Ten-year outcome including patterns of failure and toxicity for adjuvant whole abdominopelvic irradiation in high-risk and poor histologic feature patients with endometrial carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 54 2 (2002 Oct 1) 527-535
35. Jolly S., Vargas C.E., Kumar T., Weiner S.A., Brabbins D.S., Chen P.Y., et al. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation. Gynecol. Oncol. 103 1 (2006 Oct) 87-93
36. Mundt A.J., Murphy K.T., Rotmensch J., Waggoner S.E., Yamada S.D., and Connell P.P. Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 50 5 (2001 Aug 1) 1154-1160
37. Sutton G., Axelrod J.H., Bundy B.N., Roy T., Homesley H., Lee R.B., et al. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. Gynecol. Oncol. 100 2 (2006 Feb) 349-354
38. Creutzberg C.L., van Putten W.L., Koper P.C., Lybeert M.L., Jobsen J.J., Warlam-Rodenhuis C.C., et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet 355 9213 (2000 Apr 22) 1404-1411
39. Sutton G., Axelrod J.H., Bundy B.N., Roy T., Homesley H.D., Malfetano J.H., et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol. Oncol. 97 3 (2005 Jun) 755-763
40. Burke T.W., Gershenson D.M., Morris M., Stringer C.A., Levenback C., Tortolero-Luna G., et al. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma. Gynecol. Oncol. 55 1 (1994 Oct) 47-50
41. Muggia F.M., Blessing J.A., Sorosky J., and Reid G.C. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 20 9 (2002 May 1) 2360-2364
42. Aapro M.S., van Wijk F.H., Bolis G., Chevallier B., van der Burg M.E., Poveda A., et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann. Oncol. 14 3 (2003 Mar) 441-448
43. Thigpen J.T., Blessing J.A., Homesley H., Creasman W.T., and Sutton G. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 33 1 (1989 Apr) 68-70
44. Ball H.G., Blessing J.A., Lentz S.S., and Mutch D.G. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol. Oncol. 62 2 (1996 Aug) 278-281
45. Fleming G.F., Filiaci V.L., Bentley R.C., Herzog T., Sorosky J., Vaccarello L., et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann. Oncol. 15 8 (2004 Aug) 1173-1178
46. Murphy K.T., Rotmensch J., Yamada S.D., and Mundt A.J. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 55 5 (2003 Apr 1) 1272-1276
47. Smith M.R., Peters III W.A., and Drescher C.W. Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma. Am. J. Obstet. Gynecol. 170 6 (1994 Jun) 1677-1681 discussion 81-2
48. Hoskins P.J., Swenerton K.D., Pike J.A., Wong F., Lim P., Acquino-Parsons C., et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J. Clin. Oncol. 19 20 (2001 Oct 15) 4048-4053
49. Akram T., Maseelall P., and Fanning J. Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. Am. J. Obstet. Gynecol. 192 5 (2005 May) 1365-1367
50. du Bois A., Burges A., Meier W., Pfisterer J., Schmalfeldt B., Richter B., et al. Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR). Ann. Oncol. 17 1 (2006 Jan) 93-96
51. Sorbe B., Andersson H., Boman K., Rosenberg P., and Kalling M. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int. J. Gynecol. Cancer. 18 4 (2008 Jul-Aug) 803-808
52. Michener C.M., Peterson G., Kulp B., Webster K.D., and Markman M. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma. J. Cancer. res. Clin. Oncol. 131 9 (2005 Sep) 581-584
53. Secord A.A., Havrilesky L.J., Carney M.E., Soper J.T., Clarke-Pearson D.L., Rodriguez G.C., et al. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. Int. J. Clin. Oncol. /. Japan. Soc. Clin. Oncol. 12 1 (2007 Feb) 31-36
54. Sovak M.A., Hensley M.L., Dupont J., Ishill N., Alektiar K.M., Abu-Rustum N., et al. Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study. Gynecol. Oncol. 103 2 (2006 Nov) 451-457
55. Sovak M.A., Dupont J., Hensley M.L., Ishill N., Gerst S., Abu-Rustum N., et al. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int. J. Gynecol. Cancer 17 1 (2007 Jan-Feb) 197-203
56. Pignata S., Scambia G., Pisano C., Breda E., Di Maio M., Greggi S., et al. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br. J. Cancer 96 11 (2007 Jun 4) 1639-1643
57. Alektiar K.M., McKee A., Lin O., Venkatraman E., Zelefsky M.J., McKee B., et al. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?. Int. J. Radiat. Oncol. Biol. Phys. 54 1 (2002 Sep 1) 79-85
58. Hamilton C.A., Cheung M.K., Osann K., Chen L., Teng N.N., Longacre T.A., et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br. J. Cancer 94 5 (2006 Mar 13) 642-646
59. Sakuragi N., Hareyama H., Todo Y., Yamada H., Yamamoto R., Fujino T., et al. Prognostic significance of serous and clear cell adenocarcinoma in surgically staged endometrial carcinoma. Acta. Obstet. Gynecol. Scand. 79 4 (2000 Apr) 311-316